DERM

Journey Medical Corporation

$4.42

-2.21%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Source: Yahoo Finance
AI summary

Price & performance

1M-29.8%
3M-28.5%
YTD-31.7%
1Y-30.6%
52-week range—
Beta1.00
Full chart and returns against a benchmark

Q-Score

53/ 100

Quality against peers; 50 is the peer median.

Growth52
Risk53
Performance58
Valuation53
Profitability52
Leverage38
Sentiment57
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$61.2M+11.1%
Net income-$11.4M
Net margin-18.7%+7.9 pts
Historical fundamentals

Red flags in filings

1active red flag
Going-concern doubtMar 26, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

DERMIndustryP/E—35.25P/S1.872.74EV/EBITDA—16.35P/B3.882.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, after the close
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate